Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShaji KumarKWKatja WeiselQMQiufei Ma

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kumar et al. (2024) studied this question.

synapsesocial.com/papers/68e66c68b6db6435875f7869https://doi.org/10.1200/jco.2024.42.16_suppl.7561
View Full Paper
Ask AI
Bookmark
Share